Zeltiq Aesthetics

Last updated
Zeltiq
Company type Subsidiary
Industry Cryolipolysis
Founded2005
FounderMitchell Levinson
Headquarters
Pleasanton, California
,
United States
Key people
Mark J. Foley, president and chief executive officer
ProductsCoolSculpting Procedure
Parent Allergan plc
Website zeltiq.com   OOjs UI icon edit-ltr-progressive.svg

Zeltiq Aesthetics is a subsidiary of AbbVie based in Pleasanton, California that markets and licenses devices used for cryolipolysis procedures. The company was founded in 2005 and raised $75 million in funding before going public in 2011. It was acquired by Allergan in February 2017 for $2.48 billion. [1] [2] [3] Which was then acquired by AbbVie in 2020 for $63 billion. [4]

Contents

History

Zeltiq was founded in 2005 as Juniper Medical, Inc., by Mitch Levinson, who had previously led Thermage, a company that sold devices for radio frequency skin tightening. [5] [6] The company changed its name to Zeltiq in July 2007. [7]

The company developed a medical device to remove fat using a process called cryolipolysis, which it branded as "CoolSculpting". [8] The device works by pulling a piece of flesh between two paddles, which cool it to below freezing and hold the temperature there for a half hour or so. Afterwards the flesh is frozen and numb; the numbness persists for two to three months. [9] For the clinics that use it, there is a high capital investment, and a room is tied up for a relatively long time. [9] It is intended for body contouring and not general weight loss. As of 2013, clinical trials have found that Cryolipolysis is moderately effective and has mostly mild and temporary side effects. [10]

Cryolipolysis was invented by Rox Anderson and colleagues [11] and Juniper Medical exclusively licensed patent filings on the invention from Massachusetts General Hospital when Juniper was founded. [6] An early prototype was created to test the method on pigs, [12] and preliminary results from a clinical trial were reported in 2009. [11]

In 2009 Gordie Nye was appointed CEO, replacing Levinson, who remained on the board. [13] [14]

Zeltiq brought the device to market first for use in numbing the skin prior to dermatology procedures being done; Zeltiq received FDA clearance to market it for this purpose under the de novo pathway in 2010. [15] [16] While the company did not market its device for removing fat at that time, doctors on its scientific board were talking about that use at scientific meetings and on TV news, and doctors started using it off-label for "body-sculpting". [17] [18]

The company made money from selling the machines, and also charged doctors for each procedure they did with the machine. [5] Because the procedure was elective surgery, people paid out of pocket for it. [17] By the end of 2010, the company had raised $75 million in financing over four rounds of funding. [19]

The device received FDA clearance to be marketed for removing love handle fat from people's sides in September 2010 [20] and from the stomach in 2012. [20] It has also been approved by Health Canada and the European Union. [21] By late 2010 CoolSculpting had been introduced as a body-sculpting procedure in Europe, Asia and Canada. [22] By 2011, Zeltiq was approved to market the procedure in 46 countries. [23]

CoolSculpting became popular in the United States around 2011. [20] In the first half of that year, Zeltiq's revenues grew four-fold to $31.6 million, though it was still operating at a small loss. [5] [23] Zeltiq filed for an initial public offering later that year. [5] [23] The IPO raised $91 million. [24]

By January 2012, there had been 150,000 CoolSculpting treatments. [25] In 2014, Zeltiq introduced a new model of the CoolSculpting device obviating the suction cup and was cleared by the FDA for use on thighs. [26] [27]

As of 2014 the company's device led the market for cryolipolysis. [28] [9] [29] [30]

In February 2017 Zeltiq was purchased by Allergan for $2.48 billion. [2] [3]

As of June 2020, CoolSculpting has been cleared to treat the abdomen, love handles (flanks) upper arm, back fat, bra fat, banana roll, submental area, and thighs. [31]

CoolSculpting side effects

Linda Evangelista claims CoolSculpting procedure she underwent resulted in an uncommon side effect paradoxical adipose hyperplasia, experienced by under 1% of the patients, and causing fatty tissue to thicken and expand, the outcome contrary to the expected from the procedure. [32] Other studies, however, indicate that side effects are common on a per-patient basis, since a typical patient receives multiple treatments. [33]

Side effects under 1% (1 on 100) are called: "uncommon" by EMA, while they need to be under 1 on 1,000, to be called: "rare" and under 1 on 10,000, to be called: "very rare". If the side effect equals 1%, EMA scale calls it a "common" side effect. [34]

Related Research Articles

<span class="mw-page-title-main">Botulinum toxin</span> Neurotoxic protein produced by Clostridium botulinum

Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.

Mesotherapy is a form of alternative medicine which involves intradermal or subcutaneous injections of pharmaceutical preparations, enzymes, hormones, plant extracts, vitamins, and/or other ingredients such as hyaluronic acid. It has no proven clinical efficacy and poor scientific backing. Mesotherapy injections allegedly target adipose fat cells, apparently by inducing lipolysis, rupture and cell death among adipocytes. The stated aim of mesotherapy is to provide the skin with essential nutrients, hydration, and other beneficial compounds to rejuvenate and revitalize its appearance.

<span class="mw-page-title-main">Laser hair removal</span> Process of hair removal by exposure to laser pulses

Laser hair removal is the process of hair removal by means of exposure to pulses of laser light that destroy the hair follicle. It had been performed experimentally for about twenty years before becoming commercially available in 1995–1996. One of the first published articles describing laser hair removal was authored by the group at Massachusetts General Hospital in 1998. Laser hair removal is widely practiced in clinics, and even in homes using devices designed and priced for consumer self-treatment. Many reviews of laser hair removal methods, safety, and efficacy have been published in the dermatology literature.

<span class="mw-page-title-main">Breast augmentation</span> Surgical procedure

Breast augmentation and augmentation mammoplasty is a cosmetic surgery technique using breast-implants and fat-graft mammoplasty techniques to increase the size, change the shape, and alter the texture of the breasts. Although in some cases augmentation mammoplasty is applied to correct congenital defects of the breasts and the chest wall in other cases it is used purely as a cosmetic surgery, primary breast augmentation changes the aesthetics – of size, shape, and texture – of healthy breasts.

<span class="mw-page-title-main">Medtronic</span> Irish tax-registered medical device company

Medtronic plc is an American-Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">R. Rox Anderson</span> American dermatologist and photomedicine researcher

Richard Rox Anderson, FAAD, is a Boston-based dermatologist and entrepreneur.

<span class="mw-page-title-main">Breast implant</span> Prosthesis used to change the size, shape, and contour of a persons breast

A breast implant is a prosthesis used to change the size, shape, and contour of a person's breast. In reconstructive plastic surgery, breast implants can be placed to restore a natural looking breast following a mastectomy, to correct congenital defects and deformities of the chest wall or, cosmetically, to enlarge the appearance of the breast through breast augmentation surgery.

Injection lipolysis is a controversial cosmetic procedure in which drug mixtures are injected into patients with the goal of destroying fat cells. This practice, using drugs generally based on phosphatidylcholine and deoxycholate (PCDC), evolved from the initial intravenous use of those drug formulations to treat blood disorders.

<span class="mw-page-title-main">Liposuction</span> Surgery to remove unwanted fat

Liposuction, or simply lipo, is a type of fat-removal procedure used in plastic surgery. Evidence does not support an effect on weight beyond a couple of months and does not appear to affect obesity-related problems. In the United States, liposuction is the most common cosmetic surgery.

Aesthetic medicine is a branch of modern medicine that focuses on altering natural or acquired unwanted appearance through the treatment of conditions including scars, skin laxity, wrinkles, moles, liver spots, excess fat, cellulite, unwanted hair, skin discoloration, spider veins and or any unwanted externally visible appearance. Traditionally, it includes dermatology, oral and maxillofacial surgery, reconstructive surgery and plastic surgery, surgical procedures, non-surgical procedures, and a combination of both. Aesthetic medicine procedures are usually elective. There is a long history of aesthetic medicine procedures, dating back to many notable cases in the 19th century, though techniques have developed much since then.

Avita Medical is a clinical and commercial company developing and marketing a range of respiratory and regenerative products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

CoolSculpting is the brand name for a type of cryolipolysis procedure. Cryolipolysis is a non-invasive method of fat removal which uses extreme cold to freeze subcutaneous adipose tissue in certain localized areas of the body to reduce areas of fat. It is Food and Drug Administration (FDA)-approved for treatment of the submental area, under the jawline, the upper arms, lumbar rolls, brassiere rolls, flank area, abdomen, thighs, and under the buttocks. CoolSculpting is among the most widely used forms of cryolipolysis. Often the terms "cryolipolysis" and "CoolSculpting" are used synonymously or interchangeably.

<span class="mw-page-title-main">Edwards Lifesciences</span> American biotechnology company

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; and Singapore; and is building a new facility due to be completed in 2021 in Limerick, Ireland.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Fat removal procedures are used mostly in cosmetic surgery with the intention of removing unwanted adipose tissue. The procedure may be invasive, as with liposuction, or noninvasive using laser therapy, radiofrequency, ultrasound or cold to reduce fat, sometimes in combination with injections.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

References

  1. ↑ "Allergan Will Buy Zeltiq for $2.48 Billion". Fortune. Retrieved 2023-12-14.
  2. 1 2 "Allergan to Acquire ZELTIQ, Best-in-Class Company in Fast-Growing Body Contouring Segment, for $2.47 Billion" . Retrieved 2017-11-01.
  3. 1 2 "Meet one of the most important medical entrepreneurs you've never heard of". BostonGlobe.com. Retrieved 2017-11-01.
  4. ↑ "Three factors that drove the transformational integration of AbbVie, Allergan". abbvie.com. November 30, 2022. Retrieved December 14, 2023.
  5. 1 2 3 4 Avalos, George (July 13, 2014). "Pleasanton-based Zeltiq files for $115 million IPO". San Jose Mercury News. Archived from the original on March 4, 2016.
  6. 1 2 "Zeltiq Amendment No. 8 to Form S-1". Zeltiq via SEC Edgar. 18 October 2011.
  7. ↑ ZELTIQ Aesthetics, Inc.; Yahoo Profile, Yahoo, retrieved January 28, 2015
  8. ↑ "CoolSculpting". February 4, 2021.
  9. 1 2 3 Kabir Sarbana; Vijay K. Garg (July 1, 2014). Lasers in Dermatological Practice. JP Medical Ltd. p. 356. ISBN   978-93-5152-300-0.
  10. ↑ H. Ray Jalian & Mathew M. Avram (March 2013). "Cryolipolysis: a historical perspective and current clinical practice". Seminars in Cutaneous Medicine and Surgery. 32 (1): 31–34. PMID   24049927.
  11. 1 2 Jancin, Bruce (April 2009). "Cryolipolysis on Track to Become First Cool Way to Remove Cellulite". Skin & Allergy News. Vol. 40. p. 11.
  12. ↑ Mathew Avram (March 9, 2015). Fat Removal: Invasive and Non-invasive Body Contouring. John Wiley & Sons. pp. 102ff. ISBN   978-1-4443-3428-9.
  13. ↑ Brown, Steven (September 29, 2009). "Zeltiq Aesthetics changes CEOs". San Francisco Business Times. Retrieved January 28, 2015.
  14. ↑ "Diary:Movers and Shakers". Chemistry & Industry. November 9, 2009.
  15. ↑ "DEN090002, K080521: Device Classification under Section 513(f)(2)(de novo)". FDA. August 24, 2010. Retrieved 9 June 2018.
  16. ↑ Weintraub, Karen (March 29, 2010). "Who might be a candidate?". The Boston Globe.
  17. 1 2 Louis, Catherine (February 4, 2010). "Zap or Chill? Targeting Fat Without Surgery". The New York Times. p. E.1. Retrieved January 28, 2015.
  18. ↑ Louis, Catherine (June 30, 2010). "Beauty Spots". The New York Times. Retrieved January 28, 2015.
  19. ↑ Martino, Maureen (June 3, 2010). "Zeltiq raises $25M for fat-reduction tech". FierceMedicalDevices. Retrieved September 28, 2014.
  20. 1 2 3 Stevens, W. G.; Pietrzak, L. K.; Spring, M. A. (2013). "Broad Overview of a Clinical and Commercial Experience With CoolSculpting". Aesthetic Surgery Journal. 33 (6): 835–846. doi: 10.1177/1090820X13494757 . ISSN   1090-820X. PMID   23858510.
  21. ↑ Boey, Gerald E.; Wasilenchuk, Jennifer L. (2014). "Enhanced clinical outcome with manual massage following cryolipolysis treatment: A 4-month study of safety and efficacy". Lasers in Surgery and Medicine. 46 (1): 20–26. doi:10.1002/lsm.22209. ISSN   0196-8092. PMC   4265298 . PMID   24338439.
  22. ↑ Lee, Jenny (August 23, 2010). "Lose those love handles". The Vancouver Sun. Retrieved September 28, 2014.
  23. 1 2 3 Cowan, Lynn (October 10, 2011). "Zeltiq Is Next Week's IPO". Wall Street Journal. Retrieved January 28, 2015.
  24. ↑ Spears, Lee (October 19, 2011). "Zeltiq Aesthetics Raises $91 Million in Initial Public Offering". Bloomberg. Retrieved September 28, 2014.
  25. ↑ Uken, Cindy (January 11, 2012). "Non-invasive procedure popular method to get rid of unwanted 'love handles'". The Billings Gazette. pp. C1. Retrieved September 28, 2014.
  26. ↑ Stahl, Stephanie (May 27, 2014). "Health: Procedure Now Approved To Melt Fat Off Thighs". CBS News. Retrieved October 11, 2014.
  27. ↑ Leuty, Ron (April 14, 2014). "Hot on 'cool' thighs, Zeltiq wins FDA clearance for fat-chilling procedure". BizJournals. Retrieved October 7, 2014.
  28. ↑ Coppola, Gabrielle (September 29, 2014). "Manhattan Analysts Lose Belly Fat". Bloomberg. Retrieved September 28, 2014.
  29. ↑ Fulmer, Melinda (August 16, 2013). "With cosmetic treatments, more men enlist in battle of the bulges". Los Angeles Times. Archived from the original on October 12, 2014. Retrieved October 11, 2014.
  30. ↑ Woolston, Chris (November 8, 2010). "Freezing fat might shrink it". Los Angeles Times. Retrieved September 26, 2014.
  31. ↑ "Department of Health & Human Services" (PDF). November 16, 2016.
  32. ↑ "Why Linda Evangelista Waited to Tell Son About Fat-Freezing Trauma: 'He Shouldn't Have to Support Me'". People. February 17, 2022.
  33. ↑ "A Beauty Treatment Promised to Zap Fat. For Some, It Brought Disfigurement". New York Times. April 16, 2023.
  34. ↑ "How are the words 'rare' and 'common' defined for side effects? | Q and A | HIV i-Base". i-base.info. Retrieved 2022-08-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.